News | May 31, 2021
Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Dr. Reddy's has the rights to distribute 250mn doses in India
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
As of 2nd May 2021, the Government has provided more 16.54 crore COVID-19 vaccine doses to States/UTs free of cost
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Subscribe To Our Newsletter & Stay Updated
